Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III Trial.
Hans J SalwenderAhmet ElmaagacliMaximilian MerzKaya MiahAxel BennerMathias HaenelChristian JehnElias Karl MaiUta BertschIgor W BlauChristof ScheidDirk HoseAnja SeckingerAnna JauchMarc S RaabSteffen P LuntzBritta BesemerMarkus MunderPeter BrossartStephan FuhrmannHans-Walter LindemannKatja C WeiselJan DuerigHartmut GoldschmidtPublished in: Leukemia (2021)